• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912.

作者信息

Shanafelt Tait D, Wang Xin Victoria, Hanson Curtis A, Paietta Elisabeth, O'Brien Susan, Barrientos Jacqueline, Jelinek Diane F, Braggio Esteban, Leis Jose F, Zhang Cong Christine, Barr Paul M, Cashen Amanda F, Mato Anthony R, Singh Avina K, Mullane Michael P, Little Richard F, Erba Harry, Stone Richard M, Litzow Mark, Tallman Martin, Kay Neil E

机构信息

Department of Medicine, Stanford University, Stanford CA.

Dana Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, MA.

出版信息

Blood Adv. 2025 Jan 14;9(1):224-228. doi: 10.1182/bloodadvances.2024013474.

DOI:10.1182/bloodadvances.2024013474
PMID:39163612
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11788128/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c002/11788128/a3b97dfcf921/BLOODA_ADV-2024-013474-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c002/11788128/0863f5ab60e5/BLOODA_ADV-2024-013474-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c002/11788128/a3b97dfcf921/BLOODA_ADV-2024-013474-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c002/11788128/0863f5ab60e5/BLOODA_ADV-2024-013474-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c002/11788128/a3b97dfcf921/BLOODA_ADV-2024-013474-gr2.jpg

相似文献

1
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912.在E1912研究中接受依鲁替尼治疗的慢性淋巴细胞白血病患者中，根据IGHV突变状态评估的耐受性和长期疾病控制情况
Blood Adv. 2025 Jan 14;9(1):224-228. doi: 10.1182/bloodadvances.2024013474.
2
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.伊布替尼-利妥昔单抗与化疗免疫治疗慢性淋巴细胞白血病的长期疗效：E1912 试验的更新结果。
Blood. 2022 Jul 14;140(2):112-120. doi: 10.1182/blood.2021014960.
3
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).西班牙接受伊布替尼单药治疗的慢性淋巴细胞白血病患者的真实世界特征和结局（IBRORS-LLC 研究）。
Clin Lymphoma Myeloma Leuk. 2021 Dec;21(12):e985-e999. doi: 10.1016/j.clml.2021.07.022. Epub 2021 Aug 3.
4
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.伊布替尼联合利妥昔单抗与化疗免疫治疗慢性淋巴细胞白血病的比较
N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073.
5
Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.未突变的慢性淋巴细胞白血病中依赖布鲁顿酪氨酸激酶（BTK）的细胞增殖增强，使其对依鲁替尼的敏感性增加。
Oncotarget. 2016 Jan 26;7(4):4598-610. doi: 10.18632/oncotarget.6727.
6
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.伊布替尼、氟达拉滨、环磷酰胺和奥滨尤珠单抗（iFCG）方案治疗伴有IGHV 突变且无 TP53 异常的慢性淋巴细胞白血病（CLL）。
Leukemia. 2021 Dec;35(12):3421-3429. doi: 10.1038/s41375-021-01280-8. Epub 2021 May 18.
7
Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia.重新评估化学免疫疗法在慢性淋巴细胞白血病中的作用。
Expert Rev Hematol. 2020 Jan;13(1):31-38. doi: 10.1080/17474086.2020.1697226. Epub 2019 Dec 10.
8
Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial.伊布替尼治疗方案与化疗免疫治疗相比能更有效地激活 CD8+T 细胞：E1912 试验的免疫监测结果。
Blood. 2024 Jan 4;143(1):57-63. doi: 10.1182/blood.2023020554.
9
HELQ and EGR3 expression correlate with IGHV mutation status and prognosis in chronic lymphocytic leukemia.HELQ 和 EGR3 的表达与慢性淋巴细胞白血病中的 IGHV 突变状态和预后相关。
J Transl Med. 2021 Jan 23;19(1):42. doi: 10.1186/s12967-021-02708-6.
10
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.A041202 研究的随访结果显示，伊布替尼方案对老年 CLL 患者仍具疗效。
Blood. 2024 Apr 18;143(16):1616-1627. doi: 10.1182/blood.2023021959.

引用本文的文献

1
Back from (BTKi) holiday.从（布鲁顿酪氨酸激酶抑制剂）假期归来。
Blood Adv. 2025 Jan 14;9(1):222-223. doi: 10.1182/bloodadvances.2024014309.

本文引用的文献

1
Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.固定疗程伊布替尼-维奈托克治疗伴有合并症的慢性淋巴细胞白血病患者。
NEJM Evid. 2022 Jul;1(7):EVIDoa2200006. doi: 10.1056/EVIDoa2200006. Epub 2022 May 13.
2
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.基于微小残留病灶评估的慢性淋巴细胞白血病治疗策略
N Engl J Med. 2024 Jan 25;390(4):326-337. doi: 10.1056/NEJMoa2310063. Epub 2023 Dec 10.
3
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.初治慢性淋巴细胞白血病的维奈托克联合治疗方案。
N Engl J Med. 2023 May 11;388(19):1739-1754. doi: 10.1056/NEJMoa2213093.
4
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.伊布替尼联合利妥昔单抗与氟达拉滨、环磷酰胺和利妥昔单抗治疗初治慢性淋巴细胞白血病患者（FLAIR）：一项多中心、开放标签、随机、3 期临床试验的中期分析。
Lancet Oncol. 2023 May;24(5):535-552. doi: 10.1016/S1470-2045(23)00144-4.
5
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.伊布替尼-利妥昔单抗与化疗免疫治疗慢性淋巴细胞白血病的长期疗效：E1912 试验的更新结果。
Blood. 2022 Jul 14;140(2):112-120. doi: 10.1182/blood.2021014960.
6
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.阿卡替尼联合或不联合奥滨尤妥珠单抗对比苯丁酸氮芥联合奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病（ELEVATE TN）：一项随机、对照、III 期临床试验。
Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2.
7
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.伊布替尼联合利妥昔单抗与化疗免疫治疗慢性淋巴细胞白血病的比较
N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073.
8
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.维奈托克联合奥滨尤妥珠单抗治疗伴有合并症的 CLL 患者
N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4.
9
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.伊布替尼联合奥滨尤妥珠单抗与苯丁酸氮芥联合奥滨尤妥珠单抗一线治疗慢性淋巴细胞白血病（ILLUMINATE）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3.
10
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.伊布替尼方案与化疗免疫治疗在未经治疗的老年 CLL 患者中的比较。
N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1.